Curis Announces Conditional Approval Of Erivedge In EU - Quick Facts

(RTTNews) - Curis Inc. (CRIS) announced that the European Commission has granted conditional approval to Erivedge for the treatment of adult patients with symptomatic metastatic basal cell carcinoma or locally advanced BCC inappropriate for surgery or radiotherapy. The company said the conditional approval makes Erivedge the first licensed treatment in Europe for patients with advanced basal cell carcinoma.

As a result of the conditional approval, Curis earned a $6 million milestone payment from Genentech, a member of the Roche Group (ROG.SW, RO.SW), and will continue to be entitled to receive royalties on future sales of Erivedge. Roche is responsible for commercializing Erivedge in the EU.